Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
PLoS One ; 19(1): e0297141, 2024.
Article in English | MEDLINE | ID: mdl-38277354

ABSTRACT

Non-muscle invasive papillary urothelial carcinoma is a prevalent disease with a high recurrence tendency. Good prognostic and reproducible biomarkers for tumor recurrence and disease progression are lacking. Currently, WHO grade and tumor stage are essential in risk stratification and treatment decision-making. Here we present the prognostic value of proliferation markers (Ki67, mitotic activity index (MAI) and PPH3) together with p53, CD25 and CK20 immunohistochemistry (IHC). In this population-based retrospective study, 349 primary non-muscle invasive bladder cancers (NMIBC) were available. MAI and PPH3 were calculated manually according to highly standardized previously described methods, Ki-67 by the semi-automated QPRODIT quantification system, p53 and CD25 by the fully automated digital image analysis program Visipharm® and CK20 with the help of the semi-quantitative immunoreactive score (IRS). Survival analyses with log rank test, as well as univariate and multivariate Cox regression analyses were performed for all investigated variables. Age and multifocality were the only significant variables for tumor recurrence. All investigated variables, except gender, were significantly associated with stage progression. In multivariate analysis, MAI was the only prognostic variable for stage progression (p<0.001).


Subject(s)
Carcinoma in Situ , Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Humans , Urinary Bladder Neoplasms/pathology , Carcinoma, Transitional Cell/pathology , Tumor Suppressor Protein p53 , Immunohistochemistry , Neoplasm Recurrence, Local , Retrospective Studies , Biomarkers, Tumor , Ki-67 Antigen/metabolism , Prognosis , Carcinoma in Situ/pathology , Cell Proliferation
2.
J Urol ; 205(3): 701-708, 2021 03.
Article in English | MEDLINE | ID: mdl-33191862

ABSTRACT

PURPOSE: Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guérin treatment. Therefore, we evaluated the prognostic value of T1 substaging in patients with primary high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Patients with primary high risk nonmuscle invasive bladder cancer who received ≥5 bacillus Calmette-Guérin induction instillations were included. All tumors were centrally reviewed, which included T1 substaging (microinvasion vs extensive invasion of the lamina propria). T1 patients were stratified into high risk or highest risk subgroups according to major urology guidelines. Primary end point was bacillus Calmette-Guérin failure, defined as development of a high grade recurrence. Secondary end points were high grade recurrence-free survival, defined as time from primary diagnosis to biopsy-proven high grade recurrence and progression-free survival. Time-to-event analyses were used to predict survival. RESULTS: A total of 264 patients with high risk nonmuscle invasive bladder cancer had tumor invasion of the lamina propria, of which 73% were classified as extensive invasion and 27% as microinvasion. Median followup was 68 months (IQR 43-98) and bacillus Calmette-Guérin failure was more common among patients with extensive vs microinvasive tumors (41% vs 21%, p=0.002). The 3-year high grade recurrence-free survival (defined as bacillus Calmette-Guerin failure) for patients with extensive vs microinvasive tumors was 64% vs 83% (p=0.004). In multivariate analysis, T1 substaging was an independent predictor of high grade recurrence-free survival (HR 3.2, p=0.005) and progression-free survival (HR 3.0, p=0.009). Patients with highest risk/microinvasive disease have an improved progression-free survival as compared to highest risk/T1e disease (p.adj=0.038). CONCLUSIONS: T1 substaging provides important prognostic information on patients with primary high risk nonmuscle invasive bladder cancer treated with bacillus Calmette-Guérin. The risk of bacillus Calmette-Guérin failure is higher in extensive vs microinvasive tumors. Substaging of T1 high risk nonmuscle invasive bladder cancer has the potential to guide treatment decisions on bacillus Calmette-Guérin vs alternative strategies at diagnosis.


Subject(s)
BCG Vaccine/therapeutic use , Neoplasm Invasiveness/pathology , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology , Administration, Intravesical , Aged , BCG Vaccine/administration & dosage , Disease Progression , Female , Humans , Male , Neoplasm Staging , Netherlands , Norway , Prognosis , Retrospective Studies , Survival Analysis , Treatment Failure , Urinary Bladder Neoplasms/mortality
3.
PLoS One ; 15(6): e0233676, 2020.
Article in English | MEDLINE | ID: mdl-32484812

ABSTRACT

In urothelial cell type non-muscle invasive urinary bladder carcinoma, TNM stage and WHO grade are widely used to classify patients into low and high­risk groups for prognostic and therapeutic decision-making. However, stage and grade reproducibility and prediction accuracy are wanting. This may lead to suboptimal treatment. We evaluated whether proliferation features, nuclear area of the epithelial cancer cells and the composition of stromal and tumor infiltrating lymphocytes have independent prognostic value. In 183 primary non-muscle invasive bladder cancer patients with long follow-up (median for stage progression cohort: 119 months, range 5-173; median for tumor recurrence cohort: 82, range 3-165) proliferation features Ki67, PPH3 and Mitotic Activity Index (MAI), Mean Nuclear Area (MNA), lymphocyte subsets (CD8+, CD4+, CD25+) and plasma cells (CD138+) were assessed on consecutive sections. Post-resection instillation treatments (none, mitomycin, BCG) were strictly standardized during the intake period. Risk of recurrence was associated with expression of Ki67 (≤ 39 vs. > 39) and Multifocality (p = 0.01). Patients with low Ki67 had a higher recurrence rate than those with high Ki67. Lymphocyte composition did not predict recurrence. Stage progression was strongly associated with high values for MAI (>15) and CD25+ (>0.2%). In a multivariate analysis the combination of MAI and CD25+ was the single most prognostic feature (p<0.001). Validation of these results in additional, independent studies is warranted.


Subject(s)
Carcinoma, Transitional Cell/pathology , Lymphocytes, Tumor-Infiltrating/immunology , Mitotic Index , Neoplasm Recurrence, Local/diagnosis , Urinary Bladder Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/genetics , Carcinoma, Transitional Cell/immunology , Disease Progression , Disease-Free Survival , Female , Follow-Up Studies , Humans , Interleukin-2 Receptor alpha Subunit/metabolism , Kaplan-Meier Estimate , Ki-67 Antigen/metabolism , Lymphocytes, Tumor-Infiltrating/metabolism , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/immunology , Neoplasm Staging , Prognosis , Reproducibility of Results , Urinary Bladder/pathology , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/immunology , Urinary Bladder Neoplasms/mortality
4.
Diagn Pathol ; 14(1): 90, 2019 Aug 14.
Article in English | MEDLINE | ID: mdl-31412916

ABSTRACT

BACKGROUND: European treatment guidelines for pTa and pT1 urinary bladder urothelial carcinoma depend highly on stage and WHO-grade. Both the WHO73 and the WHO04 grading systems show some intra- and interobserver variability. The current pilot study investigates which histopathological features are especially sensitive for this undesired lack of reproducibility and the influence on prognostic value. METHODS: Thirty-eight cases of primary non-muscle invasive urothelial carcinomas, including thirteen cases with stage progression, were reviewed by three pathologists. Thirteen microscopic features were extracted from pathology textbooks and evaluated separately. Reproducibility was measured using Gwet's agreement coefficients. Prognostic ability regarding progression was estimated by the area under curve (AUC) of the receiver operating characteristics (ROC) function. RESULTS: The best reproducible features (Gwet's agreement coefficient above 0.60) were papillary architecture, nuclear polarity, cellular maturation, nuclear enlargement and giant nuclei. Nucleoli was the strongest prognostic feature, and the only feature with an AUC above 0.70 for both grading systems, but reproducibility was not among the strongest. Nuclear polarity also had prognostic value with an AUC of 0.70 and 0.67 for the WHO73 and WHO04, respectively. The other features did not have significant prognostic value. CONCLUSIONS: The reproducibility of the histopathological features of the different WHO grading systems varied considerably. Of all the features evaluated, only nuclear polarity was both prognostic and significantly reproducible. Further validation studies are needed on these features to improve grading of urothelial carcinomas.


Subject(s)
Neoplasm Invasiveness/pathology , Neoplasm Recurrence, Local/pathology , Urinary Bladder Neoplasms/pathology , Urinary Bladder/pathology , Aged , Aged, 80 and over , Carcinoma, Transitional Cell , Female , Humans , Male , Middle Aged , Neoplasm Grading/standards , Neoplasm Recurrence, Local/diagnosis , Prognosis , Reproducibility of Results , World Health Organization
5.
Tidsskr Nor Laegeforen ; 128(19): 2210-3, 2008 Oct 09.
Article in Norwegian | MEDLINE | ID: mdl-18846147

ABSTRACT

BACKGROUND: Essential tremor is probably the most common movement disorder. Still, the mechanisms underlying this condition are largely unknown. We have reason to believe that essential tremor is under-diagnosed, and that many patients because of this do not receive adequate treatment. MATERIAL AND METHODS: This review is based on own clinical experience, non-systematic search in the PubMed database, and on the available international consensus documents. RESULTS AND DISCUSSION: Essential tremor usually presents as action tremor with postural tremor as the most prominent feature. It typically starts in the arms, but may spread and include head tremor in one third of the patients. Tremor in other parts of the body is seen less frequently. Ethanol may relieve the tremor. Essential tremor usually starts in adults and progresses with age. The prevalence is unknown, but is probably in the range 0.4-3.9%. The cause is unknown, but many families seem to have an autosomal dominant inheritance. Three associated loci have been found, but genes have not been identified. Essential tremor is often considered a neurodegenerative disorder, but receptor mechanisms may also be important. Some patients also show other neurological signs like cerebellar ataxia. New findings indicate that there are two neuropathological types of essential tremor, one is associated with cerebellar Purkinje cell pathology and one with brain stem Lewy bodies. Treatment is only symptomatic. Propranolol and primidone are the first choice drugs, but at least 30% of the patients have insufficient symptomatic relief from drug therapy. Neurosurgical treatment with thalamic deep brain stimulation is an effective alternative for the most severely disabled patients.


Subject(s)
Essential Tremor , Adult , Diagnosis, Differential , Essential Tremor/diagnosis , Essential Tremor/etiology , Essential Tremor/therapy , Humans , Tremor/diagnosis , Tremor/etiology , Tremor/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...